Home/Industries/Pharmaceutical
Pharmaceutical Medical Writing, Statistics and Regulatory Documentation
Pubrica supports pharmaceutical companies and clinical research teams with medical writing, statistical analysis and regulatory documentation for small-molecule drug development. Our services cover first-in-human studies, later-phase clinical development, regulatory submissions and post-approval activities. We develop clinical study protocols, statistical analysis plans, clinical study reports structured in accordance with ICH E3, and CTD Module 2 clinical and nonclinical overviews and summaries. We also support responses to health-authority queries and prepare manuscripts and other scientific publications. A designated project lead coordinates the work across documents, helping maintain consistent data interpretation, scientific messaging and alignment with the agreed submission or publication requirements.
Each document identifies the ICH guideline and version it follows.
- One named lead throughout
- Your SOPs and templates
- Independent review, signed off
- Mutual NDA on request
- You remain the sponsor and author
Service Scope
Clinical and regulatory documents for small-molecule drug development.
We prepare clinical, statistical and regulatory documents for pharmaceutical sponsors. One named lead works across the programme, so the overview, study report and manuscript present the data consistently.
Written to
ICH E3, E6 and M4
Each deliverable states the guideline edition it follows.
Coordinated by
One named lead
One person across the protocol, analysis plan, study report and publication.
Reviewed by
A second qualified person
Independent review, quality control and reference verification, each signed off separately.
Our Services
Medical writing and regulatory documents we prepare.
Available as single documents or as a full programme. If a document depends on one we did not write, the scoping read reports on its condition first.
Documents and the guidelines they follow
Product Types
Documentation by product type.
Document requirements differ by product. Orphan indications rely on data from small populations, over-the-counter products need labelling and safety documentation, and excipient and API suppliers need quality and compliance documentation.
Pharmaceutical segments and related sectors
Deliverables and Applications
Documents we prepare at each development stage.
Drug development runs from discovery to post-approval. You generate the science; we prepare the documents that regulators, journal editors and assessors review.
Discovery
Early scientific writing
Target rationale documents and early publications. We write up your research; we do not conduct it.
Preclinical
Nonclinical reports
Nonclinical study reports and Module 2.6 summaries, with animal work reported to ARRIVE 2.0.
Clinical
Protocol to study report
Protocols, analysis plans, ICH E3 study reports and publications planned around readouts.
Submission
Submission documents
Modules 2.4, 2.5 and 2.7, IND or NDA documents, and responses to health-authority queries.
Post-approval
Safety and lifecycle documents
PSUR and DSUR, the risk management plan, and supporting evidence for lifecycle claims.
Throughout
One named lead
Submission documents and earlier publications are kept consistent with each other.
All Services
Services available for pharmaceutical programmes.
Grouped by programme stage, so you can start with the stage you are at. Device and diagnostic services follow MDR and IVDR rather than ICH and are listed on the medical devices page instead.
64 services, by stage of the programme
Available individually or as a programme. When several run together, one named lead coordinates them so submission documents and publications stay consistent.
Who We Serve
Teams we work with in pharmaceutical companies.
The scoping read is tailored to the team that requests it.
Roles we support
Standards and Guidelines
Guidelines our documents follow.
Each deliverable names the guideline edition used and the date it was checked. When a guideline has changed recently, the deliverable states which version applies.
Guidelines relevant to small-molecule programmes
Our Use of AI
Used for search and formatting. Not used to write your science.
This policy applies to every service and every deadline.
AI use policy
How It Works
A five-step process, starting with a free scoping read.
We review your programme before providing a quote.
One
Scoping read
Two business days, at no cost. We set out the work required, the assigned team and the cost.
Two
Named team
You are told who is assigned and what they have worked on before anything starts.
Three
Outline signed off
Every section, what goes in it, which source it comes from — approved before drafting.
Four
Draft and review
Independent review, QC and reference verification, each signed off separately.
Five
Handover
The final document with its review reports, version-controlled and revised within the agreed scope.
After
Health-authority queries
The lead who wrote the document answers health-authority questions about it.
What you provide, what we provide
Send us what you have. We will tell you what is missing.
The scoping read includes an inventory of existing documents.
You send
The source
Protocol, data, previous documents, your templates and the submission date.
We send back
A written view
What exists, what is missing, what condition the existing documents are in.
Then
A scope and a figure
Quoted per programme, with the named team and the timeline, before you commit.
Our Experts
Our medical writers, statisticians and reviewers.
Writers hold a master’s degree or doctorate in life sciences, medicine or pharmacy and have at least five years of experience in the field. They are assigned by therapy area. Regulatory writers work to the guidance that governs their documents and keep up to date with it.
Specialists available for small-molecule programmes
Sample Work
Sample deliverables.
Published where the sponsor agreed, redacted where they asked.
Benefits
Benefits for pharmaceutical sponsors.
What clients told us they value.
Benefits of a single project lead
Packages
Quoted per programme, not per page.
Pricing is based on the work involved, not word count: a 4,000-word study report and a 4,000-word overview require different effort. The free scoping read produces a quote you can budget for.
First
Scoping read
Free, two business days. A written assessment of what the programme needs.
Then
A written scope
Documents, standards, named team and timeline, agreed before work starts.
Quoted
Per programme
One figure for the scope agreed, with revisions inside it rather than billed per round.
Quality Assurance
Revisions within the agreed scope.
If a deliverable does not meet the agreed scope, we rework it at no extra charge and repeat the independent review.
What the guarantee covers
FAQs
Common questions from pharmaceutical sponsors.
Both, and you set the scope. We can draft modules from source data and your input, review and revise documents your team has written, or cover sections your internal writers do not have capacity for. Your qualified staff approve every document, and the sponsor signs off.
Modules 2.4 and 2.5 (the nonclinical and clinical overviews), the 2.6 and 2.7 summaries, and the Module 5 study reports that support them. Where a submission needs a literature-based component, we conduct the search and the synthesis.
Yes, and for sponsors it is the normal arrangement. We work inside your quality system, to your document templates and your style guide, with our ISO 9001:2015 certified process underneath rather than replacing it. Where you have no template we propose one and you approve it before drafting starts.
The named lead already knows the programme and wrote the document being queried, which supports a prompt response. Tell us the deadline at the scoping read. If it cannot be met to the required standard, we will say so at the start.
Independent review by a second qualified person, then quality control, then reference verification, each signed off separately. For statistical content the analysis is checked against the plan by somebody who did not run it. The reports come with the deliverable.
We quote per programme rather than per page, because word count does not reflect the work in a dossier module. The scoping read is free, takes two business days, and sets out the scope, named team, timeline and cost before you commit.
We do not operate your pharmacovigilance system. We write the risk management plan, PSUR and DSUR, but case processing and reporting to authorities stay within your PV system, under your qualified person. We do not conduct trials: we write the protocol, analysis plan and study report, and a contract research organisation runs the study. We do not audit or certify GMP or GCP compliance. We do not put our name on your science: you remain the sponsor and author throughout.
Related Services
Services often used alongside this work.
Small-molecule programmes often need several of these services.
Adjacent work
Discuss your pharmaceutical project requirements.
Tell us the indication and submission date. The scoping read is free, takes two business days, and gives you a written assessment of what the programme needs and who would lead it.